LUNA LABS USA LLC — Department of Defense SBIR Phase I: DHA221-001

Description

Severe hemorrhage accounts for more than 90% of all survivable pre-hospital deaths sustained in military combat, so rapid hemostasis using tourniquets or an advanced hemostatic dressing is critical. While hemorrhage is responsible for the vast majority of pre-hospital deaths, infection is the leading cause of future complications including skin graft failure or sepsis. It has been demonstrated that rapid administration of therapeutics dramatically improves patient outcomes, but localized administration of these therapeutics often occurs secondary to hemostatic treatment. Luna Labs therefore proposes to design and advanced tourniquet with therapeutic delivery capabilities in which drug administration is triggered by the tightening mechanism inherent to the tourniquet itself, enabling wound treatment without changing the tourniquet application process or requiring additional input from the patient.